Clearmind Medicine Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs

Reuters

Yesterday

<a href="https://laohu8.com/S/CMND">Clearmind Medicine</a> Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs

Clearmind Medicine Inc. reported progress related to its proprietary non-hallucinogenic neuroplastogen MEAI (5-Methoxy-2-aminoindane), including continued advancement of an FDA-approved Phase I/IIa clinical trial in alcohol use disorder. The company said multiple cohorts have been completed and that trial data readouts will be presented in the future. Clearmind also cited preclinical obesity findings for MEAI published in ACS Pharmacology & Translational Science and noted new patent applications and a collaboration with Polyrizon to develop an intranasal formulation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602191305PR_NEWS_USPR_____LN91475) on February 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612628286"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612628286\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612628286?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-20 02:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612628286","market":"nz","top_or_hot":-1,"title":"Clearmind Medicine Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CMND\">Clearmind Medicine</a> Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CMNDD\">Clearmind Medicine Inc.</a> reported progress related to its proprietary non-hallucinogenic neuroplastogen MEAI (5-Methoxy-2-aminoindane), including continued advancement of an FDA-approved Phase I/IIa clinical trial in alcohol use disorder. The company said multiple cohorts have been completed and that trial data readouts will be presented in the future. Clearmind also cited preclinical obesity findings for MEAI published in ACS Pharmacology &amp; Translational Science and noted new patent applications and a collaboration with Polyrizon to develop an intranasal formulation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CMNDF\">Clearmind Medicine Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602191305PR_NEWS_USPR_____LN91475) on February 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clearmind Medicine Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClearmind Medicine Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-20 02:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CMND\">Clearmind Medicine</a> Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CMNDD\">Clearmind Medicine Inc.</a> reported progress related to its proprietary non-hallucinogenic neuroplastogen MEAI (5-Methoxy-2-aminoindane), including continued advancement of an FDA-approved Phase I/IIa clinical trial in alcohol use disorder. The company said multiple cohorts have been completed and that trial data readouts will be presented in the future. Clearmind also cited preclinical obesity findings for MEAI published in ACS Pharmacology &amp; Translational Science and noted new patent applications and a collaboration with Polyrizon to develop an intranasal formulation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CMNDF\">Clearmind Medicine Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602191305PR_NEWS_USPR_____LN91475) on February 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PLRZ","symbol_name":"Polyrizon Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL8bRMS7:1","article_id":"2612628286","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612628286","pubTimestamp":1771524345,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Clearmind Medicine Inc. reported progress related to its proprietary non-hallucinogenic neuroplastogen MEAI , including continued advancement of an FDA-approved Phase I/IIa clinical trial in alcohol use disorder. The company said multiple cohorts have been completed and that trial data readouts will be presented in the future. Clearmind also cited preclinical obesity findings for MEAI published in ACS Pharmacology & Translational Science and noted new patent applications and a collaboration with Polyrizon to develop an intranasal formulation.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PLRZ":"Polyrizon Ltd.","CMND":"Clearmind Medicine, Inc.","BK4007":"制药"},"translate_title":"随着下一代减肥治疗市场超越GLP-1药物，Clearmind Medicine报告MEAI的进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMND":0.9,"PLRZ":0.9},"content_text":"Clearmind Medicine Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs\n    \n\nClearmind Medicine Inc. reported progress related to its proprietary non-hallucinogenic neuroplastogen MEAI (5-Methoxy-2-aminoindane), including continued advancement of an FDA-approved Phase I/IIa clinical trial in alcohol use disorder. The company said multiple cohorts have been completed and that trial data readouts will be presented in the future. Clearmind also cited preclinical obesity findings for MEAI published in ACS Pharmacology & Translational Science and noted new patent applications and a collaboration with Polyrizon to develop an intranasal formulation.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602191305PR_NEWS_USPR_____LN91475) on February 19, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}